Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease

BACKGROUND: As the patents of originator biologics are expiring, biosimilar versions are becoming available for the treatment of inflammatory bowel disease (IBD). However, published switch studies of the first infliximab biosimilar, CT-P13, have delivered ambiguous results that could be interpreted...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Therap Adv Gastroenterol
Main Authors: Bergqvist, Viktoria, Kadivar, Mohammad, Molin, Daniel, Angelison, Leif, Hammarlund, Per, Olin, Marie, Torp, Jörgen, Grip, Olof, Nilson, Stefan, Hertervig, Erik, Lillienau, Jan, Marsal, Jan
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2018
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6187418/
https://ncbi.nlm.nih.gov/pubmed/30344642
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756284818801244
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados